Vivo Capital related stories
All articles and analysis
Vivo Capital raises $1.43bnThe Palo Alto-based private equity firm closed its ninth healthcare and life sciences fund above its target.
DMed Biopharma raises $50 mlnDMed Biopharmaceutical Co said it raised roughly $50 million in a Series B funding round led by Vivo Capital. Participating in the round were Legend Capital, Qiming Venture Partners and Lilly Asia Ventures. DMed is a clinical contract research organization that provides industry solutions to pharmaceutical and medical device companies in China and across the globe.
- Swift Health rakes in $45 mln Series C
Swift Health Systems, a maker of orthodontic braces, has secured $45 million in Series C funding. Vivo Capital, Novo Holdings and venBio Partners led the round.
- IGM Biosciences goes public
Mountain View, California-based IGM Biosciences Inc, a biotech firm focused on developing engineered IgM antibodies for therapeutic use, has raised about $175 million for its IPO of nearly 11 million shares at $16 per share. The stock began trading September 18, 2019 on the NASDAQ under the ticker symbol "IGMS." The lead underwriters are Jefferies, Piper Jaffray, Stifel and Guggenheim Securities. IGM's pre-IPO backers include Redmile Group, Janus Henderson Investors and Vivo Capital.
- AtriCure to acquire VC-backed SentreHEART
AtriCure Inc has agreed to acquire Redwood City, California-based SentreHEART Inc, a developer of percutaneous left atrial appendage management solutions, for upwards of $300 million. The deal is expected to close in the next several days. SentreHEART's backers include Deerfield Management Company, U.S. Venture Partners, Prospect Ventures, Vivo Capital and Decheng Capital.
- Vivo Capital racks up over $1.3 bln for ninth fund
Vivo Capital has raised over $1.3 billion for its ninth fund, according to an updated SEC filing https://www.sec.gov/Archives/edgar/data/1750117/000175011719000003/xslFormDX01/primary_doc.xml No target was listed in the document. Vivo invests in healthcare companies in the U.S. and greater China.
- NFC to buy United Family Healthcare
New Frontier Corporation has agreed to acquire United Family Healthcare, a private healthcare operator in China, for an enterprise value of $1.44 million. The sellers include TPG and Fosun Pharma. NFC's backers include Vivo Capital and Nan Fung Group.
- IGM Biosciences amasses $102 mln Series C
Mountain View, California-based IGM Biosciences Inc, a biotech firm focused on developing engineered IgM antibodies for therapeutic use, has raised $102 million in Series C financing. The investors included Redmile Group, Janus Henderson Investors and Vivo Capital.
- Revolution Medicines nabs $100 mln Series C
Redwood City, California-based Revolution Medicines Inc, a developer of medicines for cancer patients, has secured $100 million in Series C financing. The investors included Boxer Capital of the Tavistock Group, Cormorant Capital, Deerfield Management, Fidelity Management & Research Company, Vivo Capital, Biotechnology Value Fund, Nextech Invest, Schroder Adveq, The Column Group, Third Rock Ventures and Casdin Capital.